Key Takeaways
- • Countable Labs closed an oversubscribed $26 million Series funding round led by ARCH Venture Partners, with participation from F-Prime Capital and Primer Ventures, to accelerate commercialization of its single-molecule PCR technology.
- • Countable PCR delivers at least 10 times the sensitivity of conventional PCR with superior dynamic range and quantitative accuracy compared to existing digital PCR and next-generation sequencing approaches, enabling detection of rare molecular targets.
- • The funding will support development of applications across cell and gene therapy, minimal residual disease (MRD) testing, biomarker validation, vaccine quality control, and oncology diagnostics—markets demanding high analytical performance.
- • Christopher Citraro joined as Vice President of Global Sales, signaling the company's pivot toward international commercial expansion following the capital infusion.
Summary
Countable Labs announced the closing of an oversubscribed $26 million financing round to advance commercialization of Countable PCR, a proprietary single-molecule PCR platform that substantially improves upon existing molecular diagnostic technologies. The round was led by ARCH Venture Partners with additional participation from F-Prime Capital and Primer Ventures, positioning the company to execute on near-term product launches and geographic expansion.
The core innovation behind Countable PCR addresses a fundamental limitation in current molecular diagnostics: the ability to detect and quantify rare biological targets with high confidence. The platform delivers at least 10 times the sensitivity of conventional PCR while offering dynamic range and quantitative accuracy that neither digital PCR nor next-generation sequencing (NGS) has achieved at comparable cost or speed. This performance differential unlocks applications in markets where analytical precision is non-negotiable, including cell and gene therapy manufacturing, minimal residual disease (MRD) testing in oncology, biomarker validation, and vaccine quality control.
The oversubscribed nature of the round reflects investor confidence in both the technology and market opportunity. Cell and gene therapy manufacturing in particular faces quality assurance bottlenecks where existing measurement tools lack sufficient sensitivity or reproducibility. MRD testing—detecting circulating tumor DNA or residual malignant cells post-treatment—represents a high-value diagnostic market where superior sensitivity directly translates to earlier detection of recurrence and improved patient outcomes. The appointment of Christopher Citraro as Vice President of Global Sales indicates management's immediate focus on translating technical capability into commercial traction across international markets.
The funding provides Countable Labs with capital to support multiple simultaneous priorities: continued platform development to unlock the announced 10-color capability, product engineering for fit-for-purpose applications across the addressed markets, regulatory pathway navigation, and sales infrastructure buildout. The investor syndicate composition—pairing ARCH Venture Partners' deep life sciences expertise with F-Prime Capital and Primer Ventures' industry networks—suggests a coordinated approach to de-risking commercialization and accelerating customer adoption in a highly competitive diagnostics landscape.
The core innovation behind Countable PCR addresses a fundamental limitation in current molecular diagnostics: the ability to detect and quantify rare biological targets with high confidence. The platform delivers at least 10 times the sensitivity of conventional PCR while offering dynamic range and quantitative accuracy that neither digital PCR nor next-generation sequencing (NGS) has achieved at comparable cost or speed. This performance differential unlocks applications in markets where analytical precision is non-negotiable, including cell and gene therapy manufacturing, minimal residual disease (MRD) testing in oncology, biomarker validation, and vaccine quality control.
The oversubscribed nature of the round reflects investor confidence in both the technology and market opportunity. Cell and gene therapy manufacturing in particular faces quality assurance bottlenecks where existing measurement tools lack sufficient sensitivity or reproducibility. MRD testing—detecting circulating tumor DNA or residual malignant cells post-treatment—represents a high-value diagnostic market where superior sensitivity directly translates to earlier detection of recurrence and improved patient outcomes. The appointment of Christopher Citraro as Vice President of Global Sales indicates management's immediate focus on translating technical capability into commercial traction across international markets.
The funding provides Countable Labs with capital to support multiple simultaneous priorities: continued platform development to unlock the announced 10-color capability, product engineering for fit-for-purpose applications across the addressed markets, regulatory pathway navigation, and sales infrastructure buildout. The investor syndicate composition—pairing ARCH Venture Partners' deep life sciences expertise with F-Prime Capital and Primer Ventures' industry networks—suggests a coordinated approach to de-risking commercialization and accelerating customer adoption in a highly competitive diagnostics landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.